Javascript was detected to be disabled. Javascript is required for some functions on this website.

Selected Scientific Presentations

2009-2005

2009

International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 12th Annual European Congress,
Paris, France, October 24-27, 2009:

Michael Schlander and Jeff Richardson:

The Evolving Health Economics Evaluation Paradigm and the Role of the QALY.

Schmalenbach Society for Business Administration, 63. Deutscher Betriebswirtschafter-Tag,
Frankfurt am Main, Germany, October 12/13, 2009:

Introducing the Fourth Hurdle: Economic Evaluation of Pharmaceutical Products
Etablierung der Vierten Hürde: Gesundheitsökonomische Evaluation von Arzneimitteln.

(Presentation)

Institute for Quality and Efficiency in Health Care (IQWiG),
Berlin, Germany, June 30, 2009:

J. Wasem et al.:

Discussing the Feasibility of IQWiG's Methods for "Cost Benefit Evaluation".

(Aufgefordertes Korreferat zu einer Machbarkeitsstudie)

available in German: „Methodik der Kosten-Nutzen-Berwertung“

Akademie für Palliativmedizin und Hospizarbeit Dresden:
Tagung „Welches Leben ist mehr wert? Wie knappe Güter im Medizinsystem gerecht zu verteilen sind.“
Dresden, Germany, June 19-20, 2009:

A Note on the Meaning of "Efficiency' in Health Care".
[„Was bedeutet Effizienz im Gesundheitswesen?“]

Symposium of the
Konrad Adenauer Foundation, Schwerin, Germany, March 20-21, 2009:
"Europäisierung der Gesundheitssysteme? Blick ins Ausland, Perspektiven für Deutschland":

Innovation in German Health Care.
[Wie innovationsfreudig ist das deutsche Gesundheitssystem?]

The Galen Institute, Washington, DC:
Washington, DC, March 09, 2009:

Lessons from abroad for health care reform in the U.S.
"A global perspective on comparative effectiveness programs"

2008

International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 11th Annual European Congress,
Athens, Greece, November 08-11, 2008:

Expensive drugs for rare disorders and the logic of cost-effectiveness.

How much might we be prepared to pay for psychosocial interventions for patients with attention-deficit/hyperactivity disorder (ADHD)?

Cost-effectiveness of long-acting methylphenidate for treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents in Finland: an evaluation based upon a randomized clinical trial (RCT).

Health service expenditures for patients with a diagnosis of attention-deficit/hyperactivity disorder (ADHD) in Germany - an age and gender specific analysis.

Health service expenditures for children and adolescents with and without attention-deficit/hyperactivity disorder (ADHD) in Germany - impact of coexisting conditions.

Prevalence of tic disorders and coexistence with attention-deficit/hyperactivity disorder (ADHD) in a German community sample.

Administrative prevalence of psoriasis in Germany.

OÖ Ordensspitäler: 6th International Congress,
Design Center Linz, Austria, November 06, 2008:

Wertewandel in der Medizin – ein neuer medizinischer Wertekanon?

Warum und wie unterscheiden sich zentrale Wertvorstellungen von Ärzten und Ökonomen?

The Galen Institute, Washington, DC:
Washington, DC, October 30, 2008:

Comparative Effectiveness: A Perspective from Europe.

16th Cochrane Colloquium: "Evidence in the era of globalisation"
Freiburg, Germany, October 03-07, 2008:

Symposium "Can we bridge the gap between evidence-based medicine and economic evaluation?"

Marketing-Club Südhessen
Darmstadt, Germany, October 6, 2008:

Ende des Pharma-Marketing – Steht das Marketing der forschenden Arzneimittelunternehmen vor dem Aus?

Health Economics Summer School 2008,
Heidelberg / Germany, from September 29 to October 02, 2008:

Organized by the Institute for Innovation &Valuation in Health Care (InnoValHC). Details of the scientific program are available online at the Institute's website.

3. Deutscher Atherosklerosekongress
Mannheim, Germany, September 18-20, 2008:

Coronary Artery Disease:
Health Care Utilization and Economics.
[Versorgungsaspekte bei Koronarer Herzkrankheit (KHK)]

London School of Economics (LSE)
Workshop "Valuation in Health Care"
Lisboa, Portugal, June 28, 2008:

Concepts of Value in Health Care:
A Note on Value, Valuation, and Values Talk.

International Society for Pharmacoeconomics and Outcomes Research (ISPOR),
13th Annual International Meeting,
Toronto, ON, May 03-07, 2008:

Contributed Issues Panel, "QALYs Gone Wild?", with Adrian Griffin (High Wycombe, Buckinghamshire), Peter I. Juhn (New Brunswick, NJ), and Peter J. Neumann (Boston, MA).

2007

University of Heidelberg, Germany
Inaugural Address, Mannheim, December 14, 2007, 2 p.m.:

M. Schlander:

Economic Evaluation of Health Care Programs: The Case of ADHD.

(delivered in German: "Leistungsfähigkeit und Limitationen gesundheitsökonomischer Evaluationen am Beispiel der ADHS")

MEDICA Congress
Duesseldorf / Germany, November 16, 2007:

At the MEDICA Congress a roundtable discussion was devoted to issues surrounding the future of "cost-benefit evaluation" in German health care and the role of the Institute for Quality and Efficiency in Health Care (IQWiG).

Health Economics Summer School
in Heidelberg / Germany from September 24-28, 2007:

The Institute for Innovation &Valuation in Health Care (InnoValHC) offered a high-level Health Economics Summer School, comprising of an interactive one-week program focused on the foundations of (part A, September 24-25) and international experience with (part B, September 25-28) the economic evaluation of health care interventions.

13th International Congress of the European Society for Child and Adolescent Psychiatry (ESCAP),
Florence, Italy, August 25-29, 2007:

M. Schlander:

Cost-Effectiveness of ADHD Treatment Strategies: What We Do Know... and What We Do Not Know...

6th World Congress of the International Health Economics Association (iHEA),
Copenhagen, July 8-11, 2007:

M. Schlander:

Lost in Translation? Over-Reliance on QALYs May Lead to Neglect of Relevant Evidence.

(Plenary Session, July 09, 2007)

XLII Zjazd Psychiatrów Polskich, 14-16 czerwca 2007, Szczecin
[Triennual Congress of the Polish Psychiatric Association, Stettin, June 14-16, 2007]:

M. Schlander:

Leki dlugo-dzialajace na zespól nadruchliwosci z deficytami uwagi (ADHD): Czy mozliwe jest uzasadnienie ich uzycia z perspektywy ekonomicznej?
[Can we Justify the Use of Long-Acting Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) from an Economic Perspective?]

(Invited Presentation) Psychiatria Polska, Tom XLI Nr 3 - 2007, Suplement, 148.

International Center of Mental Health Policy and Economics (ICMPE)
in Venice, Italy, March 9-11, 2007:

M. Schlander:

Investing in Mental Health Policy and Econcomics Research.

Recent presentations include nine scientific posters on original research at the meeting of the International Center of Mental Health Policy and Economics in Venice.

2006

International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 9th Annual European Congress,
Copenhagen, October 29-31, 2006:

M. Schlander, O. Schwarz, L. Hakkaart-van Roijen, P.S. Jensen, U. Persson, P. Santosh, G.-E. Trott, and the MTA Cooperative Group:

Cost-Effectiveness of Clinically Proven Treatment Strategies for Attention-Deficit/Hyperactivity Disorder (ADHD) in the United States, Germany, The Netherlands, Sweden, and United Kingdom.

Value in Health 9 [6] (2006) A312.

M. Schlander, O. Schwarz, L. Hakkaart-van Roijen, P.S. Jensen, U. Persson, P. Santosh, G.-E. Trott, and the MTA Cooperative Group:

Functional Impairment of Patients with Attention-Deficit/Hyperactivity Disorder (ADHD):
An Alternative Cost-Effectiveness Analysis of Clinically Proven Treatment Strategies based upon the NIMH MTA Study.

Value in Health 9 [6] (2006) A312.

M. Schlander, O. Schwarz, L. Hakkaart-van Roijen, P.S. Jensen, U. Persson, P. Santosh, G.-E. Trott, and the MTA Cooperative Group:

Cost-Effectiveness of Clinically Proven Treatment Strategies for Attention-Deficit/Hyperactivity Disorder (ADHD):
Impact of Coexisting Conditions.

Value in Health 9 [6] (2006) A309.

M. Schlander, O, Schwarz, M. Viapiano, N. Bonauer:

Methylphenidate Prescriptions for Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD):
New Data from Nordbaden/Germany.

Value in Health 9 [6] (2006) A191-192.

M. Schlander, O, Schwarz, M. Viapiano, N. Bonauer:

Off-Label Utilization of methylphenidate (MPH) in Adults with Attention-Deficit/Hyperactivity Disorder (ADHS) in Germany: Insights from the Nordbaden Project.

Value in Health 9 [6] (2006) A311.

Monash University,
Melbourne, Victoria (Australia)
Centre for Health Economics Seminar Series,
September 14, 2006:

M. Schlander:

"Has NICE Got It Right?"

Health Technology Assessments (HTAs) by the National Institute for Health and Clinical Excellence.

17th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP),
Melbourne, VIC, September 10-14, 2006:

M. Schlander:

Cost-Effectiveness of Treatment Options for Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents: What Have We Learnt?

ACAPAP 2006 Book of Abstracts (#2040).

M. Schlander, O. Schwarz, G.-E. Trott, M. Viapiano, N. Bonauer:

Who Cares for Patients with Attention-Deficit/Hyperactivity Disorder (ADHD)? Insights from Nordbaden, Germany.

ACAPAP 2006 Book of Abstracts (#2041).

M. Schlander, O. Schwarz, G.-E. Trott, M. Viapiano, N. Bonauer:

Age and Gender Specific Comorbidity Profiles of Patients with a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD): Administrative Data from Nordbaden, Germany.

ACAPAP 2006 Book of Abstracts (#7024).

International Conference "ADHD - New Insights and Implications",
Protestant Academy Bad Boll [Evangelische Akademie Bad Boll], February 17-19, 2006:

M. Schlander:

New Evidence on Attention-Deficit/Hyperactivity Disorder (ADHD):
1. Diagnosis of ADHD: By whom and how often?
2. Cost-Effectiveness of ADHD Treatment Strategies.

Symposium "Targeted Therapy - New Perspectives in Oncology?",
National Center for Tumor Diseases (NCT),
Heidelberg / Germany, February 04, 2006:

M. Schlander:

Can We Afford "Targeted Therapies"?

2005

Pharmaceutical Round Table,
Landesapothekerkammer Baden-Wuerttemberg,
Stuttgart / Germany, December 06, 2005:

M. Schlander:

Health Economics: Is Germany a Developing Country?

7th Congress of the German Working Party on Endoprothetics,
Heidelberg / Germany, December 03, 2005:

M. Schlander:

Poltics and Economics: An Issue of Leadership?
Plus 100% in 30 Years - Can We Still Manage the System?

Annual Meeting 2005 of the German Association of Child and Adolescent Psychiatrists and Psychologists
(Jahrestagung 2005 des Berufsverbandes der Ärzte für Kinder- und Jugendpsychiatrie und Psychotherapie in Deutschland, BKJPP),
Wuerzburg, November 16-19, 2005:

M. Schlander:

Zur Zukunft der fachärztlichen Versorgung in Deutschland

(Presentation & Discussion)

International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 8th Annual European Congress,
Florence, Italy, November 06-08, 2005:

M. Schlander, O. Schwarz:

The Nordbaden Project for Health Care Utilization Research in Germany: Database Characteristics and First Application.

Value in Health 8 [6] (2005) A199.

M. Schlander, O. Schwarz, G.-E. Trott, E. Taylor, P. Santosh, P.S. Jensen, E.M. Foster, J.A. Garcia, S. Glied, M. Crowe, MTA Cooperative Group:

Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD): Are U.S. cost-effectiveness findings based upon the MTA Study relevant to mental health care policy makers in Germany?

Value in Health 8 [6] (2005) A197.

M. Schlander, O. Schwarz, G.-E. Trott, M. Viapiano, N. Bonauer:

Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents: Mental Health and Physical Co-Morbidity in Nordbaden / Germany.

Value in Health 8 [6] (2005) A196-197.

M. Schlander, O. Schwarz, G.-E. Trott, M. Viapiano, N. Bonauer:

Attention-Deficit/Hyperactivity Disorder (ADHD) in Grown-Ups: Administrative Data on Co-Existing Conditions.

Value in Health 8 [6] (2005) A196.

Winner of ISPOR Contributed Research Award for Best Poster Presentation (out of ~750 Posters)

Joint Annual Meeting 2005 of the American Academy of Child & Adolescent Psychiatry (AACAP, 52nd Annual Meeting) and the Canadian Academy of Child and Adolescent Psychiatry (CACAP, 25th Annual Meeting),
Toronto, ON, October 18-23, 2005:

L. Eugene Arnold, B. Molina, J. Swanson, J. Epstein, M. Schlander, P. Jensen:

New ADHD Insights from MTA Data Through 36 Months.

Scientific Proceedings, 25, p.54.

M. Schlander and the MTA Cooperative Group:

Cost-Effectiveness of ADHD Treatments by Diagnostic Subgroups and Comorbidity.

Scientific Proceedings, 25D, p. 55.

M. Schlander, O. Schwarz, G.-E. Trott, M. Viapiano, N. Bonauer:

Administrative Prevalence and Comorbidity of ADHD in Children and Adolescents - Evidence from Nordbaden / Germany.

Scientific Proceedings, C69, p. 150.

Colloquium on Pharmaceutical Industry Perspectives,
Princeton, NJ, October 18, 2005:

M. Schlander:

The German Pharmaceutical Market - Perspectives after the Federal Elections of 2005.

5th World Congress of the International Health Economics Association (iHEA),
Barcelona, July 2005:

M. Schlander:

Health economic evaluation of medical interventions: answering questions people are unwilling to ask?

Book of Abstracts, pp. 354-355.

M. Schlander, P.S. Jensen, E.M. Foster, O. Schwarz, & the MTA Cooperative Group:

Incremental Cost-Effectiveness Ratios of Clinically Proven Treatments for Attention-Deficit/Hyperactivity Disorder (ADHD): Impact of Diagnostic Criteria and Comorbidity.

Book of Abstracts, pp. 194-195.

10th Annual "Handelsblatt", Meeting of the Pharmaceutical Industry,
Berlin, March 16-17, 2005:

Prof. M. Schlander

M. Schlander (Moderator):

NICE - A Model for Germany?

Plenum Roundtable Discussion with
Martin Buxton (Professor of Health Economics, Brunel University),
Andrew Dillon (CEO, NICE),
Rainer Hess (Head of the German Federal Joint Committee, Gemeinsamer Bundesausschuss), and
Stefan Oschmann (VP Europe, MSD).

Plenum Discussion